Establishment of Joint Venture Aimed at the Development of Therapeutics for the Treatment of Coronavirus Disease

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company ("PeptiDream") (TSE:4587), Fujitsu Limited ("Fujitsu") (TSE:6702), Mizuho Capital Co., Ltd. ("Mizuho Capital") which is a consolidated subsidiary of Mizuho Financial Group, Inc., Takenaka Corporation and KISHIDA CHEMICAL CO., LTD. ("KISHIDA CHEMICAL") have agreed today to establish PeptiAID Inc..("PeptiAID"), a joint venture company that will research and develop peptide therapeutics capable of neutralizing both the current SARS-CoV-2 virus (Coronavirus Disease "COVID-19") and potentially any future Coronavirus ("CoV") outbreaks that may occur.